Profile data is unavailable for this security.
About the company
Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company's lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.
- Revenue in USD (TTM)614.06m
- Net income in USD-18.00m
- Incorporated1989
- Employees1.00k
- LocationAmarin Corporation PLCGemini House, Bartholomews WalkDUBLIN FK7 9JQIrelandIRL
- Phone+353 16699020
- Websitehttp://www.amarincorp.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sundial Growers Inc | 48.32m | -163.45m | 1.83bn | 394.00 | -- | 3.68 | -- | 37.96 | -0.9523 | -1.17 | 0.1979 | 0.229 | 0.1514 | 1.00 | 2.80 | 122,641.60 | -51.26 | -- | -82.14 | -- | 15.07 | -- | -338.68 | -- | 3.70 | -3.99 | 0.0053 | -- | -4.16 | -- | -44.57 | -- | -- | -- |
| Kura Oncology Inc | 0.00 | -89.63m | 1.85bn | 88.00 | -- | 3.03 | -- | -- | -1.69 | -1.69 | 0.00 | 9.23 | 0.00 | -- | -- | 0.00 | -20.16 | -28.85 | -21.15 | -30.79 | -- | -- | -- | -- | -- | -- | 0.0117 | -- | -- | -- | -41.95 | -- | 102.35 | -- |
| IGM Biosciences Inc | 0.00 | -81.36m | 1.86bn | 107.00 | -- | 4.86 | -- | -- | -2.64 | -2.64 | 0.00 | 11.94 | 0.00 | -- | -- | 0.00 | -24.29 | -- | -25.27 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -88.61 | -- | -- | -- |
| bluebird bio Inc | 250.73m | -618.70m | 1.87bn | 1.21k | -- | 1.37 | -- | 7.46 | -9.95 | -9.95 | 4.03 | 20.40 | 0.1429 | -- | 626.84 | 206,705.70 | -35.27 | -31.85 | -40.16 | -34.58 | 97.85 | -- | -246.75 | -681.64 | -- | -- | 0.00 | -- | 461.25 | 77.88 | 21.65 | -- | 32.66 | -- |
| Axsome Therapeutics Inc | 0.00 | -102.90m | 1.89bn | 60.00 | -- | 16.63 | -- | -- | -2.77 | -2.77 | 0.00 | 3.04 | 0.00 | -- | -- | 0.00 | -50.60 | -60.46 | -57.37 | -71.84 | -- | -- | -- | -- | -- | -38.64 | 0.2981 | -- | -- | -- | -50.56 | -- | 17.83 | -- |
| Revance Therapeutics Inc | 15.33m | -282.09m | 1.91bn | 470.00 | -- | 4.95 | -- | 124.83 | -4.85 | -4.85 | 0.2642 | 5.41 | 0.0289 | -- | 16.76 | 32,606.38 | -53.20 | -50.74 | -58.86 | -56.12 | 68.50 | -- | -1,840.71 | -3,963.97 | 7.29 | -24.93 | 0.3254 | -- | 3,610.65 | 119.61 | -76.94 | -- | 4.84 | -- |
| Morphic Holding Inc | 44.95m | -45.00m | 1.93bn | 89.00 | -- | 11.97 | -- | 42.90 | -1.48 | -1.48 | 1.45 | 4.53 | 0.1835 | -- | 8.34 | 505,000.00 | -18.37 | -- | -21.68 | -- | -- | -- | -100.12 | -- | -- | -- | 0.00 | -- | 164.74 | -- | -3.86 | -- | -- | -- |
| Amarin Corporation plc (ADR) | 614.06m | -18.00m | 1.95bn | 1.00k | -- | 3.10 | -- | 3.17 | -0.0507 | -0.0507 | 1.59 | 1.60 | 0.6645 | 0.9897 | 4.53 | 614,060.00 | -1.95 | -14.03 | -2.77 | -21.66 | 78.59 | 77.19 | -2.93 | -19.18 | 2.25 | -- | 0.00 | -- | 42.89 | 49.67 | 20.51 | -- | 55.18 | -- |
| Jufeel International Group | 19.35m | 6.62m | 1.95bn | 144.00 | -- | -- | 260.34 | 100.76 | 0.2362 | 0.2362 | 0.6904 | 1.17 | 0.4034 | 1.77 | 24.22 | 134,392.90 | 14.07 | -- | 22.24 | -- | 77.98 | -- | 34.87 | -- | 0.114 | -- | 0.0249 | -- | -36.72 | -- | -56.36 | -- | -- | -- |
| BioCryst Pharmaceuticals, Inc. | 17.81m | -182.81m | 1.97bn | 246.00 | -- | -- | -- | 110.81 | -1.09 | -1.09 | 0.1065 | -0.1089 | 0.0699 | 0.4762 | 1.16 | 72,406.51 | -71.69 | -62.76 | -117.19 | -115.79 | 90.59 | 92.33 | -1,026.35 | -370.13 | 3.00 | -28.90 | 1.08 | -- | -63.53 | -18.07 | -67.88 | -- | -36.86 | -- |
| NGM Biopharmaceuticals Inc | 87.37m | -102.49m | 1.98bn | 210.00 | -- | 6.50 | -- | 22.64 | -1.49 | -1.49 | 1.28 | 3.97 | 0.2463 | -- | 15.01 | 416,038.10 | -28.89 | -- | -32.68 | -- | -- | -- | -117.31 | -- | -- | -- | 0.00 | -- | -15.62 | -- | -139.48 | -- | -- | -- |
| China Zhong Qi Holdings Ltd | 1.19m | 820.58k | 2.00bn | 3.00 | 0.0164 | 1.36 | -- | 1,687.04 | 60.97 | 60.97 | 88.08 | 0.7339 | 14.21 | -- | 185.24 | -- | 983.85 | -117.92 | -- | -- | 79.48 | 78.10 | 69.22 | -122.76 | -- | -- | 0.00 | -- | 1,568.27 | 32.30 | 172.76 | -- | -- | -- |
| MacroGenics Inc | 104.88m | -129.74m | 2.02bn | 370.00 | -- | 6.40 | -- | 19.25 | -2.55 | -2.55 | 2.00 | 5.26 | 0.3035 | -- | 5.86 | 283,467.60 | -37.54 | -31.27 | -43.58 | -35.91 | -- | -- | -123.70 | -110.93 | -- | -- | 0.00 | -- | 63.40 | 0.7865 | 14.54 | -- | -8.48 | -- |
| Madrigal Pharmaceuticals Inc | 0.00 | -202.24m | 2.02bn | 42.00 | -- | 8.16 | -- | -- | -13.09 | -13.09 | 0.00 | 15.47 | 0.00 | -- | -- | 0.00 | -55.48 | -28.86 | -61.53 | -31.16 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -140.92 | -- | -- | -- |
| CytoDyn Inc | 0.00 | -159.18m | 2.04bn | 19.00 | -- | -- | -- | -- | -0.3137 | -0.3137 | 0.00 | -0.0111 | 0.00 | -- | -- | 0.00 | -196.90 | -375.22 | -1,959.47 | -- | -- | -- | -- | -- | 0.2741 | -3.05 | 1.15 | -- | -- | -- | -121.41 | -- | 17.20 | -- |
| Myriad Genetics, Inc. | 557.00m | -244.40m | 2.05bn | 2.70k | -- | 2.28 | -- | 3.68 | -3.27 | -3.00 | 7.46 | 11.68 | 0.3717 | 6.46 | 5.36 | 206,296.30 | -16.32 | -- | -17.86 | -- | 68.01 | -- | -43.90 | -- | 2.48 | -20.80 | 0.2033 | -- | -- | -- | -- | -- | -- | -- |
Data as of Apr 20 2021. Currency figures normalised to Amarin Corporation PLC's reporting currency: US Dollar USD
23.14%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Baker Bros. Advisors LPas of 31 Dec 2020 | 27.99m | 7.11% |
| Eversept Partners LPas of 31 Dec 2020 | 15.94m | 4.05% |
| BVF Partners LPas of 31 Dec 2020 | 10.76m | 2.73% |
| Tavistock Life Sciences Co. (Investment Management)as of 31 Dec 2020 | 6.00m | 1.52% |
| Avoro Capital Advisor LLCas of 31 Dec 2020 | 6.00m | 1.52% |
| Grosvenor Capital Management LPas of 31 Dec 2020 | 5.89m | 1.50% |
| SCP Investment LPas of 31 Dec 2020 | 5.50m | 1.40% |
| ClearBridge Investments LLCas of 31 Dec 2020 | 4.63m | 1.18% |
| Rock Springs Capital Management LPas of 31 Dec 2020 | 4.20m | 1.07% |
| Morgan Stanley & Co. LLCas of 31 Dec 2020 | 4.18m | 1.06% |
More ▼
Data from 31 Dec 2020 - 31 Dec 2020Source: FactSet Research Systems Inc.
